BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrecor (B-type Natriuretic Peptide)--which may be beneficial to the management of these two diseases--or placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: Scios, Inc.
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• acute admission to hospital with CHF exacerbation

• calculated creatinine clearance between 15-60ml/min using the Cockroft Gault equation.

Exclusion Criteria:

• hypotension (SBP < 90mmHg)

• hypertension (SBP > 170 mmHg) necessitating vasodilator therapy

• known allergy to Natrecor

• history of heart transplantation

• contraindications to vasodilator therapy (i.e. severe aortic stenosis)

• up-front use of inotropes

• mental incompetence meaning inability to provide informed consent